PI
SLNO

PEAK6 Investments’s Soleno Therapeutics SLNO Stock Holding History

PEAK6 Investments’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-826
Closed -$11K – 5744
2021
Q3 		$11K Buy
+826
New +$11.5K ﹤0.01% 4856

Other funds holding SLNO

A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
OC
Oppenheimer & Co New York $9.37B AUM 36.4% 1-Year Est. Return

PEAK6 Investments's SLNO Position: Q4 2021 in Review

PEAK6 Investments sold out of Soleno Therapeutics (SLNO) in Q4 2021, closing a stake of 826 shares — an estimated $11K sold.

PEAK6 Investments first reported a position in SLNO in Q3 2021 and held it in 1 quarter. The position peaked at $11K in Q3 2021. 39 funds tracked by Wall St. Rank hold SLNO as of Q4 2021.

  • PEAK6 Investments reported no remaining Soleno Therapeutics position as of Q4 2021 after selling out during the quarter.
  • PEAK6 Investments sold 826 Soleno Therapeutics shares in Q4 2021, an estimated $11K.
  • PEAK6 Investments first reported a position in Soleno Therapeutics in Q3 2021 and held it in 1 quarter.
  • PEAK6 Investments's Soleno Therapeutics position peaked at $11K in Q3 2021.
  • 39 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q4 2021.

Based on PEAK6 Investments's 13F filing for Q4 2021, filed 11 Feb 2022.